Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Lymphoma
Related studies linked through entity extraction aliases.
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
- Status
- TERMINATED
- Phase
- NA
Melphalan With BBBD in Treating Patients With Brain Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
- Status
- TERMINATED
- Phase
- NA
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage
- Status
- COMPLETED
- Phase
- PHASE3
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
- Status
- COMPLETED
- Phase
- PHASE2